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Immunofluorescence Analysis of Villous
Trophoblasts: A Tool for Prenatal Diagnosis of
Inherited Epidermolysis Bullosa with Pyloric Atresia
Marina D’Alessio1, Giovanna Zambruno1, Alexandra Charlesworth2,3, Jean-Philippe Lacour2,3,4 and
Guerrino Meneguzzi2,3
Genetic mutations invalidating the genes for integrin a6b4 and, in some cases, plectin are associated with
junctional and simplex epidermolysis bullosa with pyloric atresia (PA-JEB and PA-EBS), respectively. These
recessive inherited conditions are characterized by pregnancies with fetal bullae, pyloric atresia, poly-
hydramnios, and neonatal mucocutaneous blistering, which often results in early postnatal demise. To date,
first-trimester DNA-based prenatal diagnosis is not applicable to affected kindred carrying as yet unidentified
genetic mutations. Here, we show that first-trimester chorionic villi strongly express both integrin a6b4 and
plectin, which persist throughout the pregnancy. Based on this observation, we implemented 25 prenatal
diagnoses in kindred at risk for PA-EB by immunomapping, which identified three PA-JEB-affected fetuses and
22 healthy ones. In 19 cases, including the three PA-JEB pregnancies that were prematurely terminated, the
results were confirmed by chorionic villous DNA-based tests, which also led to the identification of seven
previously unreported mutations in the a6b4 integrin genes. Our prediction was further sustained by the birth
of 22 healthy babies. These results validate chorionic villi immunofluorescence examination as a tool for
prenatal diagnosis of PA-JEB and PA-EBS and indicate that this procedure could be devised for EB with muscular
dystrophy, which is also associated with genetic mutations in plectin.
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INTRODUCTION
Over the last decades, the exponential growth of knowledge
on the molecular bases of inherited skin disorders has greatly
facilitated their diagnosis, prognosis prediction, and disease
management. With respect to inherited epidermolysis bullosa
(EB), the characterization of the individual cutaneous base-
ment membrane components has helped to shed light on the
molecular basis of this heterogeneous group of disorders.
Similar in their etiology of trauma-induced blistering and
erosions of the skin and mucous membranes (Fine et al.,
2000), but widely ranging in their clinical presentation,
inherited EB had traditionally been divided into three major
categories: EB simplex (EBS), junctional EB (JEB), and dystro-
phic EB (DEB), which are characterized by tissue separation
within the epidermal basal cell layer, the lamina lucida of the
basement membrane, and the sublamina densa, respectively
(Fine et al., 2000). Within these three major categories, there
are to date as many as 30 different recognized EB subtypes
resulting from genetic mutations in 10 distinct genes enco-
ding seven adhesion proteins, which play a critical role in the
anchorage of the epidermis to the underlying dermis (Fine
et al., 2000; Uitto and Richard, 2005; Has and Bruckner-
Tuderman, 2006). The abnormal expression and/or function
of any of these proteins results in the dermal–epidermal
detachment distinctive of all the EB forms. However, the
nature and the combination of the genetic mutations, as well
as the expression pattern of the mutated molecule in extra-
cutaneous tissues, cooperate in determining the specific
EB variant and the related phenotype (Varki et al., 2006;
Varki et al., 2007). Genetic mutations resulting in absent/
highly reduced expression of laminin 332, integrina6b4, and
collagen type VII are known to cause the severe recessive EB
variants Herlitz JEB (OMIM 226700), JEB associated with
pyloric atresia (PA-JEB, OMIM 226730) and Hallopeau–
Siemens DEB (OMIM 226600), respectively (Uitto and
Richard, 2005). In addition, mutations in the hemidesmomal
component plectin underlie the recessive diseases EBS with
pyloric atresia (PA-EBS) and EBS with muscular dystrophy
(OMIM 226670) and the rare dominantly inherited form of
EBS designated as EBS Ogna type (OMIM 131950) (Uitto and
Richard, 2005). In all these EB forms, immunofluorescence
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examination of a patient’s skin biopsy shows defective
expression of the involved protein, thus facilitating the
identification of the causative gene and the subsequent
search for mutations. As for most inherited disorders, no
effective therapy is currently available for these life-threaten-
ing conditions, thus prenatal diagnosis remains the only
option for pregnant women at risk for recurrence. Initially,
this procedure relied upon ultrastructural analysis of
mid-pregnancy fetal biopsy specimens to detect the skin
abnormalities characteristic of each EB form (Rodeck et al.,
1980); then immunofluorescence procedures were developed
to gain additional information on the defective protein and
mutated gene (Holbrook et al., 1993). After identification of
the EB causative genes, this approach of prenatal diagnosis
was replaced by DNA-based genetic analysis of first-trimester
chorionic villi, which permits an earlier assessment of the
fetus phenotype (Fassihi et al., 2006). Despite these advant-
ages, the DNA-based prenatal diagnosis does not apply to
affected kindred carrying unidentified genetic mutations.
Previous studies have shown that, in the placenta, the
cytotrophoblast villus stem cells strongly express the laminin
receptor integrin a6b4 (Aplin, 1993; Damsky et al., 1992).
This integrin concentrates at the basal aspect of the cells
and anchors them to the basement membrane rich in
laminins and collagen type IV (Aplin, 1993; Damsky et al.,
1992). Based on this observation, we hypothesized that other
molecules responsible for severe EB forms could be expressed
in these placental structures and that immunofluorescence
examination of first trimester chorionic villi could permit
early prenatal diagnosis of severe EB in families at risk of
recurrence even when the causative genetic mutation(s) are
not yet identified. To verify this idea, we examined a series of
placental villi for the expression of all the proteins known to
be defective in the severe EB forms. Our analysis demon-
strated that, in addition to integrin a6b4, the chorionic villi
strongly express the intermediate filament binding protein
plectin and validated the working hypothesis that a novel
early prenatal diagnostic procedure for PA-JEB and PA-EBS
can be based on chorionic villi immunostaining.
RESULTS AND DISCUSSION
Expression of the basement membrane proteins involved in
the etiology of severe EB was examined in frozen samples of
placental villi obtained from 10- to 15-week-gestation preg-
nancies at risk for diseases unrelated to EB using specific
monoclonal and polyclonal antibodies. According to pre-
viously published data (Aplin, 1993; Damsky et al., 1992), a
strong immunolabeling was detected with antibodies directed
against the integrin a6 and b4 subunits (Figure 1a and b) and
to the a6b4 heterodimer (not shown). Interestingly, the villous
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Figure 1. Immunofluorescence staining pattern of integrin a6b4 and plectin in chorionic villous samples. Immunofluorescence labeling of frozen
chorionic villous samples of (a–c) a healthy control and (d–i) pregnancies at risk for PA-EB using (a, d, g) monoclonal antibodies G0H3, (b, e, h) 3E1, and
(c, f, i) 10F6 to integrins a6, b4, and plectin, respectively. In the chorionic villi of the healthy 11-week-gestation fetus, a comparable and intense staining
signal for integrins (a) a6, (b) b4, the a6b4 heterodimer (not shown) and (c) plectin localizes at the cytotrophoblast surface and concentrates at the
basement membrane zone. In the trophoblasts of the 28- and the 37-week fetuses (Table 1, samples 23, 25, respectively), the immunofluorescence analysis
showed a strong reduction of (d) integrin a6 or (h) integrin b4, respectively, thus indicating PA-JEB. The immunolabeling of (e) integrin b4 and (f) plectin
of the 28-week fetus, and (g) of integrin a6 and (i) plectin of the 35-week fetus was similar with the controls. The corresponding fetuses resulted homozygous
and compound heterozygous for nonsense mutations in the ITGA6 or the ITGB4 genes, respectively. Bar¼68 mm.
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cytotrophoblasts were also immunoreactive to anti-plectin
antibodies (Figure 1c), whereas no immunostaining was
visualized with the antibodies directed against laminin 332,
and type VII collagen (not shown). Finally, a strong immuno-
reactivity to collagen type IV, used as positive control, was
visible throughout the villous stroma at the level of basement
membranes (not shown). The labeling pattern observed for
both plectin and integrin a6b4 was very similar, with an
immunofluorescence staining localized at the basal cell aspect
of the cytotrophoblasts and at the lateral and apical areas of
contact between the contiguous cells (Figure 1a–c). These data
demonstrate that first trimester villous trophoblasts express the
component of the hemidesmosomal inner plaque plectin and
confirm the previously reported expression of integrin a6b4
in these placental cells (Aplin, 1993; Damsky et al., 1992). To
our knowledge, this is previously unreported. In addition,
the coexpression of plectin and integrin a6b4 at the basal
aspect of the cytotrophoblasts suggests the presence of type II
hemidesmosomes. Indeed, several in vitro studies have shown
that integrin a6b4 and plectin are the two key adhesion
molecules involved in the initial steps of hemidesmosome
nucleation and both are expressed in the gastrointestinal tract
where rudimentary type II hemidesmosomes are detected
(Green and Jones, 1996).
The severe EB forms PA-JEB and PA-EBS are genetically
determined by mutations in the genes ITGA6, ITGB4, and PLEC,
encoding the two subunits of the a6b4 integrin and plectin,
respectively (Uitto and Richard, 2005; Has and Bruckner-
Tuderman, 2006). Clinically indistinguishable, these two
recessively inherited conditions are characterized by pregnan-
cies with fetal eruption of bullae, pyloric atresia, polyhydram-
nios, severe neonatal mucocutaneous blistering, and early
postnatal demise (Uitto and Richard, 2005). All the genetic
mutations described so far in PA-JEB and PA-EBS patients cause
either absence or markedly reduced expression of the mutated
protein, which can be easily detected by immunofluorescence
examination of a skin biopsy (Uitto and Richard, 2005). Thus,
the detection of plectin and integrin a6b4 in chorionic villi
supported the rationale for investigating the feasibility of
prenatal diagnosis for PA-JEB and PA-EBS by immuno-
fluorescence examination of placental villi. Twenty-five pre-
natal diagnoses involving 18 kindred who had requested
testing for PA-EB were evaluated by both protein immunodetec-
tion and screening of genetic mutations (Table 1). In 22 of the
pregnancies, the test was requested because of disease
recurrence risk, and therefore it was carried out on first-trimester
villous samples (Table 1, samples 1–22). For three villous
samples, the testing was obtained from late gestations in women
referred to the Department of Dermatology in Nice because
of abnormal ultrasound findings and elevated amniotic fluid
a-fetoprotein (Table 1, samples 23–25) (Azarian et al., 2006).
By immunofluorescence analysis, all 22 first-trimester villous
cytotrophoblasts proved to be immunoreactive to the mono-
clonal antibodies directed against the integrin subunits a6, b4,
and plectin, and with an intensity and distribution of the signal
staining indistinguishable from the controls (Table 1, samples
1–22). With respect to the genetic analyses, 10 of these
pregnancies concerned previously genotyped PA-JEB kindred
(Table 1, samples 13–22), 7 of which had genetic abnormalities
in the integrin b4 gene (ITGB4), whereas 3 had genetic
abnormalities in integrin a6 gene (ITGA6). The other 12 cases
concerned PA-EB kindred who had not been genotyped
(Table 1, samples 1–12). In accordance with the normal expres-
sion of integrin a6b4 and plectin observed by immunofluores-
cence, which predicted an unaffected fetus, in all pregnancies
from genotyped families, sequence analysis of fetal DNA
showed the presence of at least one normal allele (Table 1,
samples 13–22), whereas in 6 out of the 12 samples of kindred
who had not previously been genotyped, the implementation of
mutation analysis allowed confirmation of 6 unaffected children
(Table 1, samples 1–6). For the remaining 6 villous samples, the
candidate gene and the causative mutations remained unknown
(Table 1, samples 7–12). Thus, at this stage, 16 early prenatal
diagnoses were based on results obtained by both immuno-
fluorescence analysis and genetic studies. In the remaining six
pregnancies at risk of recurrence, the prenatal diagnosis
exclusively relied on the immunofluorescence data without
further confirmation at the genetic level (Table 1, samples 7–12).
Nevertheless, after genetic counseling, the families declined
further prenatal testing by fetal skin biopsy and opted for
periodical follow-up to detect any possible ultrasonographic or
laboratory signs of pyloric atresia that could invalidate the
conclusion of the immunofluorescence tests (Lepinard et al.,
2000). As predicted, all 22 pregnancies proceeded without
complications, and at birth all the newborns were healthy.
During the study, prenatal diagnosis was also requested for
three late gestations in which polyhydramnios and elevated
amniotic fluid a-fetoprotein were associated with a positive
acetylcholinesterase in kindred with no family history of PA-EB
(Table 1, samples 23–25). In one case, in utero ultrasound
examination had in addition visualized extensive fetal skin
blistering (Table 1, sample 25) (Azarian et al., 2006). In accor-
dance with the clinical observation, immunofluorescence
analysis of the chorionic villi obtained from these three
fetuses showed a strong staining reduction of either the a6
(Table 1, sample 23) (Figure 1d) or b4 (Table 1, samples 24, 25)
(Figure 1h) integrin subunits, as compared with control samples
of the same gestation age. Plectin immunoreactivity of the
suspected PA-EB fetuses was instead comparable with the
control (Figure 1c, f and i). After genetic counseling, and in
accordance with the French laws, the families opted for
termination of the pregnancies. As expected, the aborted fetuses
presented all clinical manifestations of severe PA-EB with
extremely fragile integument and extensive areas of congenital
aplasia cutis. Immunofluorescence examination of skin biopsy
samples from the fetus aborted at 37 weeks showed a complete
detachment of the epithelium from the underlying dermis and
confirmed the defective expression of b4 integrin (Figure S1).
No frozen skin samples were available from the other two
aborted fetuses. Subsequent mutational screening showed the
presence of genetic mutations, which invalidated the expres-
sion of integrin a6b4 in the three fetuses. During this study,
14 different mutations in the ITGB4 and 2 in the ITGA6 gene
were identified, 7 of which are previously unpublished. All
novel mutations are predicted to impair integrin a6b4 expres-
sion. Specifically, six mutations (c591_592insC, c93delG,
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c2140insC, pW1240X, pR1540X within ITGB4, and pR540X
in the ITGA6 gene) were nonsense or small out-of-frame
insertions or deletions resulting in premature termination codon
downstream of the site of the genetic lesion. One mutation
(c1377-2A4G in the ITGB4 coding sequence of sample 1) was
a single-base substitution, which abolishes the 30 acceptor
splice site consensus sequence and is expected to cause
an aberrant pre-mRNA processing resulting in downstream
premature termination codon. In conclusion, this study demons-
trates that the chorionic villi strongly express the hemidesmo-
somal component a6b4 integrin and its protein interactor
plectin from first trimester to the end of the pregnancy. On these
bases, we have developed and validated a novel prenatal test
for PA-JEB that can be extended to PA-EBS. This procedure,
which is relatively safe for the fetus, is simple, rapid, and acces-
sible to all the laboratories equipped for immunohistological
analysis. It also represents the only possible prenatal diagnostic
approach for pregnancies either with no family history of PA-EB
or at risk of recurrence but not yet genotyped. Besides
establishing the phenotype of the fetus, the villi immunolabeling
detects the defective polypeptide, which designates the candi-
date gene and facilitates the screening for genetic mutations.
Indeed, given the minute amount of villi required for
immunolabeling, epitope mapping can be coupled with genetic
analysis in pregnancies at risk for recurrence of PA-EB carrying
as yet unidentified genetic mutations. Immunodetection of
integrin a6b4 and plectin represents an additional diagnostic
tool for any abnormal gestation when, in addition to no family
Table 1. Correlation between the immunofluorescence staining pattern of integrin a6b4 and plectin in the fetal
villous trophoblasts and probands’ genotype and phenotype
Sample
Gestational
age (weeks)
IF a6/b4/
plectin
Mutated
gene
Father’s
genotype
Mother’s
genotype
Fetus’
genotype
Newborn
phenotype
11 11 ++/++/+ ITGB4 c1377-2A4G c1377-2A4G wt+wt Unaffected
21 11 ++/++/+ ITGB4 Undet c567-2A4G2 Undet+wt Unaffected
31 11 ++/++/+ ITGB4 pC61Y pC61Y pC61Y+wt Unaffected
41 13 ++/++/+ ITGB4 591_592insC2 93delG2 wt+wt Unaffected
51 13 ++/++/+ ITGB4 pR252C pR252C pR252C+wt Unaffected
61 12 ++/++/+ ITGB4 pC61Y Undet Undet+wt Unaffected
7 12 ++/++/+ Undet Undet Undet Undet Unaffected
8 15 ++/++/+ Undet Undet Undet Undet Unaffected
9 15 ++/++/+ Undet Undet Undet Undet Unaffected
10 11 ++/++/+ Undet Undet Undet Undet Unaffected
11 10 ++/++/+ Undet Undet Undet Undet Unaffected
12 12 ++/++/+ Undet Undet Undet Undet Unaffected
133 11 ++/++/+ ITGB4 c1141delC c3793+2 insT c1141delC+wt Unaffected
143 10 ++/++/+ ITGB4 pC61Y pC61Y wt+wt Unaffected
153 13 ++/++/+ ITGB4 c591_592insC2 c93delG2 wt+93delG Unaffected
163 11 ++/++/+ ITGB4 pC61Y pC61Y pC61Y+wt Unaffected
173 11 ++/++/+ ITGB4 Undet pN318del Undet+wt Unaffected
183 11 ++/++/+ ITGB4 Undet pN318del wt#+pN318del Unaffected
193 12 ++/++/+ ITGB4 c2140insC2 pr283c wt+ pr283c Unaffected
203 11 ++/++/+ ITGA6 c809delC c809delC c809delC+wt Unaffected
213 11 ++/++/+ ITGA6 c809delC c809delC wt+wt Unaffected
223 10 ++/++/+ ITGA6 pR540X2 pR540X2 pR540X+wt Unaffected
231 28 +/+/+ ITGA6 pR540X2 pR540X2 pR540X+pR540X Affected
241 36 +/+/+ ITGB4 c4422_4423delCA c4422_4423delCA c4422_4423delCA+
c4422_4423delCA
Affected
251 37 +/+/+ ITGB4 pW1240X2 pR1540X2 pW1240X +pR1540X Affected
Undet, undetermined; wt, wild-type; ++, strongly positive; +, positive; +, barely detectable immunolabeling.
1The mutated gene and the causative mutation(s) were identified after prenatal diagnosis by epitope mapping.
2Novel mutations. Samples 3 and 14, 4 and 15, 7 and 8, 10 and 11, 17 and 18, 20 and 21, 22 and 23 correspond to chorionic villous samples from
consecutive pregnancies in the same family. Genetic mutations were numbered according to the translation initiation codon of the b4A (GenBank
NM_001005731.1) and a6 (GenBank X53586) integrin cDNAs. The ITGB4 mutations c1141delC, c3793+2insT, and c1377-2A4G, as well as the c809delC
in the ITGA6 gene, have been named as c1150delG, c3801+2insT, c1379-2A-G and c791delC, respectively, in previous publications.
3The kindred was already genotyped at the time of prenatal diagnosis; #, haplotype compatible with the paternal wild-type allele.
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history of PA-EB, polyhydramnios and elevated amniotic fluid
a-fetoprotein are coupled with positive acetylcholinesterase
(Lepinard et al., 2000). Our findings also indicate that prenatal
diagnosis tests based on immunofluorescence detection of
plectin could be devised for EBS with muscular dystrophy,
which is allelic to PA-EBS (Uitto and Richard, 2005). They also
suggest that prenatal testing based on epitope mapping of fetal
tissues could be applied to other inherited diseases associated
with defective expression of extracutanoeus proteins present in
the chorionic villi, such as the merosin-deficient congenital
muscular dystrophy (OMIM 607855) and microria-congenital
nephrosis syndrome (OMIM 609049), which are caused by
mutations in the genes encoding the laminin chains a2 and b2,
respectively (Korhonen and Virtanen, 2001).
MATERIALS AND METHODS
Residual chorionic villous samples from four pregnant women
requesting prenatal diagnosis for unrelated diseases were used
to investigate the expression of proteins defective in severe EB.
The study was then extended to 25 pregnancies requesting
prenatal diagnosis for PA-EB: 22 of them were at risk for recurrence
of PA-EB and studied at 10- to 15-weeks gestation, whereas the
remaining three were referred to us after the seventh month of
pregnancy, because of abnormal ultrasound findings and elevated
amniotic fluid a-fetoprotein, suggesting PA-EB (Lepinard et al., 2000).
Fourteen prenatal diagnoses involved seven mothers who had
multiple pregnancies, therefore a total of 18 EB kindred were
included in the cohort. The study had institutional approval and was
conducted according to the Declaration of Helsinki principles. All
women had received genetic counseling and gave written informed
consent. An aliquot of each chorionic villous sample was processed
for genomic DNA extraction and another aliquot was frozen for
immunofluorescence analysis. Genomic DNA was screened for
genetic mutations in the integrin a6b4 and plectin genes by PCR
amplification of the exonic DNA sequences followed by denaturing
high-performance liquid chromatography (DHPLC) scanning and/or
direct sequencing. For immunofluorescence studies, 4-mm thick
frozen sections were processed using a biotin-streptavidin-fluorescein
procedure as previously described (Kanitakis et al., 1989). Skin
biopsy samples from the fetus aborted at 37 weeks were similarly
processed for immunolabeling. The antibodies used were as follows:
G0H3 to integrin a6 (BD PharMingen Inc., San Diego, CA); 3E1
(Chemicon International, Temecula, CA), and 450-11A (from R
Falcioni, Rome, Italy) specific to the extracellular and cytoplasmic
domain of integrin b4, respectively; S3-41 (from V Quaranta,
Nashville, TN) to the heterodimeric a6b4; HD121 (from K Owaribe,
Nagoya, Japan) and 10F6 to plectin (Santa Cruz Biotechnology Inc.,
Santa Cruz, CA); GB3 to trimeric laminin 332 (from JP Ortonne, Nice,
France); BM165 to the laminin a3 chain; K140 to the laminin b3
chain (from P Marinkovich, Stanford, CA); U46 to the laminin g2
chain (Scaturro et al., 2003); CIV-22 (Dako Carpenteria, San Diego,
CA) and LH7:2 (Cymbus Bioscience, Southampton, UK) to
collagens type IV and type VII, respectively. The staining intensity
by amplified immunofluorescence was scored as follows: þ þ ,
strongly positive; þ , positive; þ /, barely detectable; , negative.
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Figure S1. Immunofluorescence staining of skin samples from a PA-JEB
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